Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Universal Platform for Living Adaptive Toxin-removal (UNI-PLAT)

Active
ARPA-H 03SBIR / STTR

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Universal Platform for Living Adaptive Toxin-removal, or UNI-PLAT, is a federal solicitation under ARPA-H 03 aimed at developing a universal synthetic biology platform designed to create next-generation microbial chassis that can be readily reprogrammed for diverse programmable functions. The primary proof-of-concept focuses on toxin removal for chronic disease management, but the platform is explicitly intended to be adaptable across multiple industries including environmental remediation, biomanufacturing, agriculture, holistic medicine, and therapeutic discovery. The goal is to establish a stable, reliable, and modular microbial system that functions like a plug-and-play tool, enabling rapid customization without compromising performance or robustness across varied operational environments. This initiative is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to organizations with fewer than 500 employees, and falls under NAICS code 541714 for research and development in the physical, engineering, and life sciences. Managed by the Advanced Research Projects Agency for Health within the Department of Health and Human Services, the solicitation was posted on June 11, 2026, with proposals due by September 30, 2027. While no specific place of performance or point of contact is listed, the project emphasizes cross-sector impact and seeks to catalyze transformative advances in living systems that go beyond the initial toxin-removal application to enable broad, scalable biological solutions.

General Info

Develop universal synthetic biology platform for programmable microbial toxin removal, targeting health and industry.

Agency

Department of Health and Human Services → Arpa-HView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

SBA

Documents

(6)

A06B Attachment B Cost Proposal Spreadsheet Template

XLSXcost-proposal

ARPA-H Small Business Program Solution Summary Submission Template

DOCXsow

A06B Attachment C Key Personnel Worksheet Template

DOCXkey-personnel-worksheet

A06B Attachment A Contract Clauses

PDFcontract-clauses

A06B Attachment E SBP Oral Technical Presentation Template

PPTXpresentation-template

ARPA-H Gantt Chart Template

XLSXsow

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

1 update
PhaseSolicitation
Posted

Solicitation

Amendment 1

Contract was updated

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment of Health and Human Services → Arpa-H
ContactsNo contacts available
OfficeUSA
Organization / Agency
Department of Health and Human Services → Arpa-H
View Agency Profile
Office AddressUSA
ContactsNo contact information available

Full Description

Show more
The purpose of this topic area is to catalyze the development of a universal, “plug-and-play” synthetic biology platform that enables next-generation microbial chassis capable of performing a broad array of programmable functions. While this solicitation primarily uses toxin removal as a proof-of-concept in relation to chronic disease management, the platform is intended to be adaptable to a range of challenges across industries such as environmental remediation, biomanufacturing, agriculture, holistic medicine, and therapeutic discovery. The broader goal is to create a stable, reliable, and easily reprogrammable microbial platform that demonstrates potential for cross-sector impact beyond the initial use case.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.
W6QK Acc-Apg

POSTED

5 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract
Solicitation # HT942626RE002
The Defense Health Agency Contracting Activity is preparing to issue an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity contract vehicle, which supports military medical research and development services across four distinct market segments: medical research and development support, general research and development support, regulatory processes for human and animal research, and translational science services for moving innovations from laboratory to clinical practice. This on-ramp opportunity is exclusively set-aside for small businesses certified under the Small Business Administration’s 8(a) Program, with the aim of expanding the pool of qualified contractors while maintaining alignment with the existing unrestricted contract vehicle. The OMNIBUS IV IDIQ has a cumulative ceiling of $10 billion and has already generated over $600 million in task order awards across 51 task orders since its base period began in 2022, with the majority of activity occurring in fiscal years 2024 through 2026. Task orders are competitively awarded, including set-asides for 8(a) participants, and may be issued by various DoD entities including DHACA, the Naval Supply Systems Command, and the Uniformed Services University of the Health Sciences. The upcoming solicitation, expected to be posted on SAM.gov in late February 2026, follows a delay to align with the February 2026 implementation of the FAR Overhaul, which significantly impacts how small business status is handled under unrestricted IDIQ contracts. Under the new rules, contractors do not need to recertify their small business status at the task order level when bidding on 8(a)-set-aside work, as they may rely on their original IDIQ-level size and status representation—even if they have graduated from the 8(a) Program or grown beyond small business size thresholds. However, contractors must still recertify their status at the IDIQ level within 60 to 120 days prior to the end of the fifth contract year, in compliance with FAR 19.301-2(b)(1)(iii)(A). Proposals must be submitted via the PIEE Solicitation module using a SAM.gov-registered account, and while the initial pre-solicitation notice provides the framework and intent, detailed evaluation criteria, submission instructions, and contract clauses will be formally outlined in the forthcoming RFP. All awards under this on-ramp will be made to small business 8(a) participants, and the government anticipates issuing multiple new contracts
Defense Health Agency

POSTED

7 days ago

DEADLINE

N/A
View Details

More opportunities from Department of Health and Human Services → Arpa-H

Same awarding agency